Mirum Pharmaceuticals (MIRM) Share-based Compensation (2019 - 2026)

Mirum Pharmaceuticals' Share-based Compensation history runs 8 years deep, the most recent figure standing at $4.5 million for Q1 2026.

• On a quarterly basis, Share-based Compensation fell 71.7% year-over-year to $4.5 million in Q1 2026; TTM through Mar 2026 was $60.1 million, a 13.82% increase from a year earlier, with the FY2025 full-year figure at $71.4 million, up 47.44% from the prior year.
• Share-based Compensation fell to $4.5 million in Q1 2026 per MIRM's latest filing, from $19.0 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $38.8 million in Q4 2024 and bottomed at -$13.7 million in Q3 2024.
• The 5-year median for Share-based Compensation is $9.7 million (2023), against an average of $10.9 million.
• Biggest YoY gain for Share-based Compensation was 5817.5% in 2024; the steepest drop was 262.81% in 2024.
• Year by year, Share-based Compensation stood at $27.0 million in 2022, then slumped by 64.01% to $9.7 million in 2023, then surged by 299.29% to $38.8 million in 2024, then slumped by 50.98% to $19.0 million in 2025, then plunged by 76.5% to $4.5 million in 2026.
• Per Business Quant, the three latest MIRM Share-based Compensation figures stand at $4.5 million (Q1 2026), $19.0 million (Q4 2025), and $18.1 million (Q3 2025).